Prediction of recurrent clostridium difficile infection at the bedside : the GEIH-CDI score
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved..
Recurrence of Clostridium difficile infection (CDI) has major consequences for both patients and the health system. The ability to predict which patients are at increased risk of recurrent CDI makes it possible to select candidates for treatment with new drugs and therapies (including fecal microbiota transplantation) that have proven to reduce the incidence of recurrence of CDI. Our objective was to develop a clinical prediction tool, the GEIH-CDI score, to determine the risk of recurrence of CDI. Predictors of recurrence of CDI were investigated using logistic regression in a prospective cohort of 274 patients diagnosed with CDI. The model was calibrated using the Hosmer-Lemeshow test. The tool comprises four factors: age (70-79 years and ≥80 years), history of CDI during the previous year, direct detection of toxin in stool, and persistence of diarrhea on the fifth day of treatment. The functioning of the GEIH-CDI score was validated in a prospective cohort of 183 patients. The area under the ROC curve was 0.72 (0.65-0.79). Application of the tool makes it possible to select patients at high risk (>50%) of recurrence and patients at low risk (<10%) of recurrence. GEIH-CDI score may be useful for clinicians treating patients with CDI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
International journal of antimicrobial agents - 51(2018), 3 vom: 06. März, Seite 393-398 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cobo, Javier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical prediction tool |
|---|
| Anmerkungen: |
Date Completed 24.08.2018 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijantimicag.2017.09.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM276097319 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM276097319 | ||
| 003 | DE-627 | ||
| 005 | 20231225011221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijantimicag.2017.09.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0920.xml |
| 035 | |a (DE-627)NLM276097319 | ||
| 035 | |a (NLM)28939450 | ||
| 035 | |a (PII)S0924-8579(17)30350-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cobo, Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prediction of recurrent clostridium difficile infection at the bedside |b the GEIH-CDI score |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2018 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. | ||
| 520 | |a Recurrence of Clostridium difficile infection (CDI) has major consequences for both patients and the health system. The ability to predict which patients are at increased risk of recurrent CDI makes it possible to select candidates for treatment with new drugs and therapies (including fecal microbiota transplantation) that have proven to reduce the incidence of recurrence of CDI. Our objective was to develop a clinical prediction tool, the GEIH-CDI score, to determine the risk of recurrence of CDI. Predictors of recurrence of CDI were investigated using logistic regression in a prospective cohort of 274 patients diagnosed with CDI. The model was calibrated using the Hosmer-Lemeshow test. The tool comprises four factors: age (70-79 years and ≥80 years), history of CDI during the previous year, direct detection of toxin in stool, and persistence of diarrhea on the fifth day of treatment. The functioning of the GEIH-CDI score was validated in a prospective cohort of 183 patients. The area under the ROC curve was 0.72 (0.65-0.79). Application of the tool makes it possible to select patients at high risk (>50%) of recurrence and patients at low risk (<10%) of recurrence. GEIH-CDI score may be useful for clinicians treating patients with CDI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Validation Study | |
| 650 | 4 | |a Clinical prediction tool | |
| 650 | 4 | |a Clostridium difficile | |
| 650 | 4 | |a Recurrence | |
| 700 | 1 | |a Merino, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Cózar-Llistó, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw, Evelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Marrodán, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Calbo, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Bereciartúa, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Muñoz, Luis A |e verfasserin |4 aut | |
| 700 | 1 | |a Salavert, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Rodríguez, M Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a García-Rosado, Dácil |e verfasserin |4 aut | |
| 700 | 1 | |a Bravo-Ferrer, J María |e verfasserin |4 aut | |
| 700 | 1 | |a Gálvez-Acebal, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Henríquez-Camacho, César |e verfasserin |4 aut | |
| 700 | 1 | |a Cuquet, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Pino-Calm, Berta |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Porto, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Félix, Borja M |e verfasserin |4 aut | |
| 700 | 0 | |a Nosocomial Infection Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, José |e investigator |4 oth | |
| 700 | 1 | |a Muriel, Alfonso |e investigator |4 oth | |
| 700 | 1 | |a Giner, Livia |e investigator |4 oth | |
| 700 | 1 | |a Boix, Vicente |e investigator |4 oth | |
| 700 | 1 | |a Ramos-Martínez, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Rocío |e investigator |4 oth | |
| 700 | 1 | |a Martos, Purificación |e investigator |4 oth | |
| 700 | 1 | |a Arch, Olga |e investigator |4 oth | |
| 700 | 1 | |a Sardiña, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Aguirre, Elena |e investigator |4 oth | |
| 700 | 1 | |a Badía, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Boix, Lucía |e investigator |4 oth | |
| 700 | 1 | |a Perales, Ildefonso |e investigator |4 oth | |
| 700 | 1 | |a De Santos-Castro, Pedro A |e investigator |4 oth | |
| 700 | 1 | |a Bratos-Pérez, Miguel Angel |e investigator |4 oth | |
| 700 | 1 | |a Cuellar, Sandra |e investigator |4 oth | |
| 700 | 1 | |a González, Eva |e investigator |4 oth | |
| 700 | 1 | |a Soto, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Sousa, Adrián |e investigator |4 oth | |
| 700 | 1 | |a Llinares, Pedro |e investigator |4 oth | |
| 700 | 1 | |a Castelo, Laura |e investigator |4 oth | |
| 700 | 1 | |a Morales, Isabel |e investigator |4 oth | |
| 700 | 1 | |a Sojo, Jesús |e investigator |4 oth | |
| 700 | 1 | |a Delgado-Iribarren, Alberto |e investigator |4 oth | |
| 700 | 1 | |a Martí, Carmina |e investigator |4 oth | |
| 700 | 1 | |a Vázquez, Rosa |e investigator |4 oth | |
| 700 | 1 | |a Mairal, Pilar |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of antimicrobial agents |d 1991 |g 51(2018), 3 vom: 06. März, Seite 393-398 |w (DE-627)NLM090678974 |x 1872-7913 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2018 |g number:3 |g day:06 |g month:03 |g pages:393-398 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijantimicag.2017.09.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2018 |e 3 |b 06 |c 03 |h 393-398 | ||